Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice

被引:76
作者
Sgouras, DN
Panayotopoulou, EG
Martinez-Gonzalez, B
Petraki, K
Michopoulos, S
Mentis, A
机构
[1] Inst Pasteur, Dept Med Microbiol, Lab Med Microbiol, Athens 11521, Greece
[2] Alexandra Hosp, Gastroenterol Clin, Athens, Greece
关键词
D O I
10.1128/CDLI.12.12.1378-1386.2005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In clinical settings, Lactobacillus johnsonii La1 administration has been reported to have a favorable effect on Helicobacter pylori-associated gastritis, although the mechanism remains unclear. We administered, continuously through the water supply, live La1 to H. pylori-infected C57BL/6 mice and followed colonization, the development of H. pylori-associated gastritis in the lamina propria, and the levels of proinflammatory chemokines macrophage inflammatory protein 2 (MIP-2) and keratinocyte-derived cytokine (KC) in the serum and gastric tissue over a period of 3 months. We documented a significant attenuation in both lymphocytic (P = 0.038) and neutrophilic (P = 0.003) inflammatory infiltration in the lamina propria as well as in the circulating levels of anti-H. pylori immunoglobulin G antibodies (P = 0.003), although we did not observe a suppressive effect of La1 on H. pylori colonizing numbers. Other lactobacilli, such as L. amylovorus DCE 471 and L. acidophilus IBB 801, did not attenuate H. pylori-associated gastritis to the same extent. MIP-2 serum levels were distinctly reduced during the early stages of H. pylori infection in the La1-treated animals, as were gastric mucosal levels of MIP-2 and KC. Finally, we also observed a significant reduction (P = 0.046) in H. pylori-induced interleukin-8 secretion by human adenocarcinoma AGS cells in vitro in the presence of neutralized (pH 6.8) La1 spent culture supernatants, without concomitant loss of H. pylori viability. These observations suggest that during the early infection stages, administration of La1 can attenuate H. pylori-induced gastritis in vivo, possibly by reducing proinflammatory chemotactic signals responsible for the recruitment of lymphocytes and neutrophils in the lamina propria.
引用
收藏
页码:1378 / 1386
页数:9
相关论文
共 55 条
[1]  
Aiba Y, 1998, AM J GASTROENTEROL, V93, P2097, DOI 10.1111/j.1572-0241.1998.00600.x
[2]   Neutrophil chemoattractant genes KC and MIP-2 are expressed in different cell populations at sites of surgical injury [J].
Armstrong, DA ;
Major, JA ;
Chudyk, A ;
Hamilton, TA .
JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 75 (04) :641-648
[3]  
Avonts L., 2001, Mededelingen Faculteit Landbouwkundige en Toegepaste Biologische Wetenschappen Universiteit Gent, V66, P543
[4]   What is the role of serology in assessing Helicobacter pylori eradication? [J].
Bergey, B ;
Marchildon, P ;
Peacock, J ;
Mégraud, F .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (06) :635-639
[5]   The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo [J].
BernetCamard, MF ;
Lievin, V ;
Brassart, D ;
Neeser, JR ;
Servin, AL ;
Hudault, S .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1997, 63 (07) :2747-2753
[6]  
BOZIC CR, 1995, J IMMUNOL, V154, P6048
[7]   Characterization and production of amylovorin L471, a bacteriocin purified from Lactobacillus amylovorus DCE 471 by a novel three-step method [J].
Callewaert, R ;
Holo, H ;
Devreese, B ;
Van Beeumen, J ;
Nes, I ;
De Vuyst, L .
MICROBIOLOGY-SGM, 1999, 145 :2559-2568
[8]   A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates [J].
Canducci, F ;
Armuzzi, A ;
Cremonini, F ;
Cammarota, G ;
Bartolozzi, F ;
Pola, P ;
Gasbarrini, G ;
Gasbarrini, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (12) :1625-1629
[9]   Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects [J].
Cats, A ;
Kuipers, EJ ;
Bosschaert, MAR ;
Pot, RGJ ;
Vandenbroucke-Grauls, CMJE ;
Kusters, JG .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (03) :429-435
[10]  
Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945